JM
Jain Madanlal Kamal Chand
About Jain Madanlal Kamal Chand
Data last updated:
Jain Madanlal Kamal Chand is a Director at Tricept Life Sciences Private Limited (since 2022), Director at Tricept Pharmaceuticals Private Limited (since 2022) and Director at Avixaa Aesthetiq Private Limited (since 2026), and holds 2 more current directorships. The companies operate in Pharma, Home Appliances and Professional Services. The 2 current companies with reported revenue have a combined latest revenue of ₹3.26 Cr; the largest is Tricept Life Sciences Private Limited at ₹3.09 Cr (FY 2024). Earlier, Jain Madanlal Kamal Chand was a Director at Power Consulting Private Limited (2007–2008).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Tricept Life Sciences Private Limited U24230TN2019PTC129881 | Director | 14 Mar 2022 | 2019 | ₹3.09 Cr (FY 2024) | Active |
 Tricept Pharmaceuticals Private Limited U51909TN2017PTC118587 | Director | 14 Mar 2022 | 2017 | ₹16.4 Lakh (FY 2022) | Active |
| Avixaa Aesthetiq Private Limited U21000TN2026PTC195491 | Director | 17 Jul 2026 | 2026 | Active | |
| National Medicines Private Limited U24231TN1999PTC042799 | Director | 23 Mar 2017 | 1999 | Active | |
| Wattyl Pharmachems Private Limited U51397TN2004PTC052463 | Director | 06 Dec 2006 | 2004 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Power Consulting Private Limited U74140TN2007PTC062311 | Director | 08 Feb 2007 | 2007 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Jain Madanlal Kamal Chand
| Name | DIN | Company | Designation |
|---|---|---|---|
| Pendiyalam Krishnamurthy Sankara Reddy Gokul Dutt | 06549933 | Tricept Life Sciences Private Limited , Avixaa Aesthetiq Private Limited | Director |
| Ganesan Magesh | 06591571 | Tricept Pharmaceuticals Private Limited | Director |
| Rameshbabu Gowri Shankar | 11833824 | Avixaa Aesthetiq Private Limited | Director/Designated Partner |
| Anuraag Jain | 00634490 | National Medicines Private Limited | Additional Director |
| Pushpa Bohara | 01895168 | Wattyl Pharmachems Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Jain Madanlal Kamal Chand
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jain Madanlal Kamal Chand
Jain Madanlal Kamal Chand currently holds 5 directorships: Tricept Life Sciences Private Limited (Director, since 14 Mar 2022, revenue ₹3.09 Cr (FY 2024)); Tricept Pharmaceuticals Private Limited (Director, since 14 Mar 2022, revenue ₹16.4 Lakh (FY 2022)); Avixaa Aesthetiq Private Limited (Director, since 17 Jul 2026); National Medicines Private Limited (Director, since 23 Mar 2017); Wattyl Pharmachems Private Limited (Director, since 06 Dec 2006).
Jain Madanlal Kamal Chand was first appointed on 06 Dec 2006 as Director at Wattyl Pharmachems Private Limited. The most recent appointment on record is 17 Jul 2026 at Avixaa Aesthetiq Private Limited.
The 2 current companies of Jain Madanlal Kamal Chand that report revenue have a combined latest revenue of ₹3.26 Cr: Tricept Life Sciences Private Limited ₹3.09 Cr (FY 2024); Tricept Pharmaceuticals Private Limited ₹16.4 Lakh (FY 2022).
Jain Madanlal Kamal Chand held 1 earlier board appointment: Power Consulting Private Limited (Director, 08 Feb 2007 to 07 May 2008).
The current boards of Jain Madanlal Kamal Chand's companies include Pendiyalam Krishnamurthy Sankara Reddy Gokul Dutt (Tricept Life Sciences Private Limited), Ganesan Magesh (Tricept Pharmaceuticals Private Limited), Rameshbabu Gowri Shankar (Avixaa Aesthetiq Private Limited), Anuraag Jain (National Medicines Private Limited), Pushpa Bohara (Wattyl Pharmachems Private Limited).